| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Dosed first patient in Phase 1/2 clinical trial for XTX501, a potential best-in-class PD-1/masked IL-2 bispecific, for patients with metastatic NSCLC, and plan to report initial Phase 1 data in the fourth quarter of 2027 |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
Received FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 |
| 12 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
In order to achieve a more equal balance of director membership among the three classes of the board of directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”) in accordance with the Company’s Restated Certificate of Incorpor... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 |
| 16 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
The non-employee directors of Xilio Therapeutics, Inc. (the “Company”) shall receive the following compensation for their service as members of the Board of Directors (the “Board”) of the Company. |
| 23 Mar 2026 |
8-K: Results of Operations and Financial Condition
XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 |
| 12 Mar 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
WALTHAM, Mass., March 12, 2026 -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that it will impl... |
| 09 Mar 2026 |
8-K: Regulation FD Disclosure
Unlocking the Potential of Immuno-Oncology Therapies March 9, 2026 © 2026 Xilio Therapeutics, Inc. ® |
| 24 Feb 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On February 23, 2026, Xilio Therapeutics, Inc. (the "Company") held a special meeting of stockholders (the "Special Meeting"). The following is a summary of the matters voted on at the Special Meeting and the results of the votes on such... |
| 12 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
As Representative of the Underwriter named in Schedule I hereto |
| 08 Jan 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027 |
| 05 Jan 2026 |
8-K: Regulation FD Disclosure
In connection with a follow-on public offering in June 2025, Xilio Therapeutics, Inc. (the “Company”) issued 66,676,000 Series B warrants to purchase common stock, which were exercisable until December 31, 2025. Through December 31, 2025... |
| 25 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
At the special meeting of stockholders of Xilio Therapeutics, Inc. (the “Company”) held on November 21, 2025 (the “Special Meeting”), the Company’s stockholders approved the Xilio Therapeutics, Inc. 2025 Stock Incentive Plan (the “2025 P... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden |
| 07 Nov 2025 |
8-K: Regulation FD Disclosure
Xilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting |
| 03 Oct 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On October 2, 2025, Xilio Therapeutics, Inc. (the “Company”) received approval from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) to transfer the listing of the Company’s common stock from ... |
| 09 Sep 2025 |
8-K: Other Events
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead |
| 28 Aug 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On August 22, 2025, Xilio Therapeutics, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it is... |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition
Announced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an anti-CTLA-4 combinatio... |
| 12 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 10, 2025, Xilio Therapeutics, Inc. (the “Company”) held its 2025 annual meeting of stockholders. The following is a summary of the matters voted on at that meeting and the results of the votes on such matters. |
Loading...